Bertil Kågedal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Bertil Kågedal has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
K. Årstrand
Department of Biomedicine and Surgery, Division of Clinical Chemistry, University Hospital, Linköping, Sweden
3 shared publicationsKerstin Årstrand
Department of Biomedicine and Surgery, Division of Clinical Chemistry, Linköping University, Linköping, Sweden and
2 shared publications- Malin Farnebäck
Dynamic Code AB, SE-582 56 Linköping, Sweden
2 shared publications A Håkansson
1 shared publicationA. Kullman
Department of Oncology, Umeå University Hospital, Umeå, Sweden
1 shared publicationA. Takasaki
1 shared publication
Latest Publications
- 31 December 2007
- Published by Elsevier in Molecular and Cellular Probes
- Vol. 21 (5-6) , 329-337
Conjugated polythiophene probes target lysosome-related acidic vacuoles in cultured primary cells
- 31 December 2007
- Published by Elsevier in Molecular and Cellular Probes
- Vol. 21 (5-6) , 329-337
Conjugated polythiophene probes target lysosome-related acidic vacuoles in cultured primary cells
- 1 January 2007
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 45 (11) , 1481-7
How useful are housekeeping genes? Variable expression in melanoma metastases
Clin Chem Lab Med 2007;45:1481–7.
- 1 January 2007
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 45 (11) , 1481-7
How useful are housekeeping genes? Variable expression in melanoma metastases
Clin Chem Lab Med 2007;45:1481–7.
- 1 October 2004
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 64 (6) , 559-564
Improved method for analysis of cysteinyldopa in human serum
5‐S‐l‐Cysteinyl‐l‐dopa is a well‐known pigment intermediate and analysis of its serum concentration is well suited for evaluation of treatment and follow‐up of stage III and IV malignant melanoma. A simplified analytical method is described using organic extraction followed by clean‐up on a boronate gel to capture the compound containing vicinal hydroxyls. Weak acid solution elutes the 5‐S‐cysteinyldopa suitable for high‐performance liquid chromatography (HPLC). The absolute recoveries of cysteinyldopa and its diastereomer 5‐S‐D‐cysteinyl‐l‐dopa (used as an internal standard) were 81.5±2.8% and 81.3±2.7%, respectively, and use of the internal standard for the whole procedure gave an analytical recovery of 101±0.8%. The limit of quantitation was 1.5 nmol/L and the imprecision of the method was <5.0% over the analytical range 1.5–500 nmol/L. The method is cheap and easy to perform and compares well with other described techniques. The use of the method is illustrated by results obtained during treatment of a patient with metastatic malignant melanoma.
- 1 October 2004
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 64 (6) , 559-564
Improved method for analysis of cysteinyldopa in human serum
5‐S‐l‐Cysteinyl‐l‐dopa is a well‐known pigment intermediate and analysis of its serum concentration is well suited for evaluation of treatment and follow‐up of stage III and IV malignant melanoma. A simplified analytical method is described using organic extraction followed by clean‐up on a boronate gel to capture the compound containing vicinal hydroxyls. Weak acid solution elutes the 5‐S‐cysteinyldopa suitable for high‐performance liquid chromatography (HPLC). The absolute recoveries of cysteinyldopa and its diastereomer 5‐S‐D‐cysteinyl‐l‐dopa (used as an internal standard) were 81.5±2.8% and 81.3±2.7%, respectively, and use of the internal standard for the whole procedure gave an analytical recovery of 101±0.8%. The limit of quantitation was 1.5 nmol/L and the imprecision of the method was <5.0% over the analytical range 1.5–500 nmol/L. The method is cheap and easy to perform and compares well with other described techniques. The use of the method is illustrated by results obtained during treatment of a patient with metastatic malignant melanoma.
- 1 August 2004
- Published by Wiley in Pigment Cell Research
- Vol. 17 (4) , 346-351
Pterin-Dependent Tyrosine Hydroxylase mRNA is not Expressed in Human Melanocytes or Melanoma Cells
Pterin-dependent tyrosine hydroxylase has been described to occur occasionally in melanocytes. It is therefore important to quantify the mRNA of this enzyme in pigment cells to understand whether this enzyme can take an active part in pigment formation. A real-time reverse transcription-polymerase chain reaction method was used to quantify tyrosine hydroxylase mRNA in melanocytes and melanoma cells. The calibrator was obtained by amplification of a segment of cDNA from tyrosine hydroxylase mRNA, which included the target thus allowing enumeration of the number of transcripts per cell. In melanocytes (n = 3), tyrosine hydroxylase mRNA ranged from non-detectable to 0.000492 transcripts/cell and in melanoma cells from non-detectable to 0.005340 transcripts/cell. In neuroblastoma cells, the median tyrosine hydroxylase mRNA number was 0.4 transcripts/cell (range 0.02-25 transcripts/cell). The amount of tyrosine hydroxylase mRNA in the pigment cells was far less than the mRNA concentrations of four melanocyte-specific proteins measured in the same melanocytes and melanoma cells. We conclude that on the average less than 1 of 1000 melanocytes and melanoma cells contains at least one tyrosine hydroxylase mRNA molecule. Consequently, in 999 of 1000 cells translation into the corresponding enzyme protein cannot occur because of the lack of an mRNA template. Thus, in these cells there is no pterin-dependent tyrosine hydroxylase that can contribute to pigment formation by producing priming amounts of l-dopa for proper function of tyrosinase.
- 1 August 2004
- Published by Wiley in Pigment Cell Research
- Vol. 17 (4) , 346-351
Pterin-Dependent Tyrosine Hydroxylase mRNA is not Expressed in Human Melanocytes or Melanoma Cells
Pterin-dependent tyrosine hydroxylase has been described to occur occasionally in melanocytes. It is therefore important to quantify the mRNA of this enzyme in pigment cells to understand whether this enzyme can take an active part in pigment formation. A real-time reverse transcription-polymerase chain reaction method was used to quantify tyrosine hydroxylase mRNA in melanocytes and melanoma cells. The calibrator was obtained by amplification of a segment of cDNA from tyrosine hydroxylase mRNA, which included the target thus allowing enumeration of the number of transcripts per cell. In melanocytes (n = 3), tyrosine hydroxylase mRNA ranged from non-detectable to 0.000492 transcripts/cell and in melanoma cells from non-detectable to 0.005340 transcripts/cell. In neuroblastoma cells, the median tyrosine hydroxylase mRNA number was 0.4 transcripts/cell (range 0.02-25 transcripts/cell). The amount of tyrosine hydroxylase mRNA in the pigment cells was far less than the mRNA concentrations of four melanocyte-specific proteins measured in the same melanocytes and melanoma cells. We conclude that on the average less than 1 of 1000 melanocytes and melanoma cells contains at least one tyrosine hydroxylase mRNA molecule. Consequently, in 999 of 1000 cells translation into the corresponding enzyme protein cannot occur because of the lack of an mRNA template. Thus, in these cells there is no pterin-dependent tyrosine hydroxylase that can contribute to pigment formation by producing priming amounts of l-dopa for proper function of tyrosinase.
- 1 October 2003
- Published by Wiley in Pigment Cell Research
- Vol. 16 (5) , 480-486
HPLC Analysis of Pheomelanin Degradation Products in Human Urine
A sensitive and specific high performance liquid chromatography (HPLC) method was developed to quantify 4‐amino‐3‐hydroxyphenylalanine (4‐AHP) and 3‐amino‐4‐hydroxyphenylalanine (3‐AHP) in urine. In degradation studies of melanin pigment, 4‐AHP and 3‐AHP are derived from benzothiazine units of pheomelanin and pheomelanin‐related metabolites such as trichochromes. 5‐S‐Cysteinyldopa‐derived benzothiazine products give 4‐AHP while 2‐S‐cysteinyldopa‐derived benzothiazine products give 3‐AHP. 3‐AHP is also derived from nitrotyrosine formed by nitration of tyrosine with reactive nitrogen species. For this reason, the influence of this biological process on the amount of 3‐AHP found in biological material have been investigated. The method is based on hydriodic acid hydrolysis of the melanin polymer and reversed‐phase HPLC with electrochemical detection of the degradation products 4‐AHP and 3‐AHP. The mobile phase consists of 25 mM ammonium acetate and sodium octanesulfonate as an ion‐pairing reagent. The 4‐AHP and 3‐AHP peaks were well separated and the detector response was linear within the range 0–2 ng injected for both compounds. With the developed chromatographic system, 4‐AHP and 3‐AHP showed good separation in the biological samples. There was a strong correlation between 4‐AHP and 3‐AHP in the urine of 50 malignant melanoma patients and two healthy subjects (R0.977). The two compounds were also strongly correlated with 5‐S‐cysteinyldopa in urine, the correlation coefficients being 0.862 and 0.907, respectively. The method described is sensitive enough for analysis of pheomelanin in urine and in several other biological samples. The results indicate that 3‐AHP in urine is not influenced by excreted 3‐nitrotyrosine and the data indicate that pheomelanins are excreted in the urine of melanoma patients.
- 1 October 2003
- Published by Wiley in Pigment Cell Research
- Vol. 16 (5) , 480-486
HPLC Analysis of Pheomelanin Degradation Products in Human Urine
A sensitive and specific high performance liquid chromatography (HPLC) method was developed to quantify 4‐amino‐3‐hydroxyphenylalanine (4‐AHP) and 3‐amino‐4‐hydroxyphenylalanine (3‐AHP) in urine. In degradation studies of melanin pigment, 4‐AHP and 3‐AHP are derived from benzothiazine units of pheomelanin and pheomelanin‐related metabolites such as trichochromes. 5‐S‐Cysteinyldopa‐derived benzothiazine products give 4‐AHP while 2‐S‐cysteinyldopa‐derived benzothiazine products give 3‐AHP. 3‐AHP is also derived from nitrotyrosine formed by nitration of tyrosine with reactive nitrogen species. For this reason, the influence of this biological process on the amount of 3‐AHP found in biological material have been investigated. The method is based on hydriodic acid hydrolysis of the melanin polymer and reversed‐phase HPLC with electrochemical detection of the degradation products 4‐AHP and 3‐AHP. The mobile phase consists of 25 mM ammonium acetate and sodium octanesulfonate as an ion‐pairing reagent. The 4‐AHP and 3‐AHP peaks were well separated and the detector response was linear within the range 0–2 ng injected for both compounds. With the developed chromatographic system, 4‐AHP and 3‐AHP showed good separation in the biological samples. There was a strong correlation between 4‐AHP and 3‐AHP in the urine of 50 malignant melanoma patients and two healthy subjects (R0.977). The two compounds were also strongly correlated with 5‐S‐cysteinyldopa in urine, the correlation coefficients being 0.862 and 0.907, respectively. The method described is sensitive enough for analysis of pheomelanin in urine and in several other biological samples. The results indicate that 3‐AHP in urine is not influenced by excreted 3‐nitrotyrosine and the data indicate that pheomelanins are excreted in the urine of melanoma patients.
- Open Access
- 1 November 2002
- Published by Taylor & Francis in BioTechniques
- Vol. 33 (5) , 1000-1002
Analysis of L-Dopa in Human Serum
- 1 November 2002
- Published by Taylor & Francis in BioTechniques
- Vol. 33 (5) , 1000-1002
Open AccessAnalysis of L-Dopa in Human Serum
- 1 June 2002
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 12 (3) , 193-200
Quantitative relationships between pigment-related mRNA and biochemical melanoma markers in melanoma cell lines
The use of reverse transcription polymerase chain reaction (RT-PCR) analysis of melanoma-specific transcripts for the identification of circulating melanoma cells has shown very variable results in different studies on melanoma patients. We have therefore developed quantitative methods to study both analytical and biological variations as possible causes of this phenomenon. Pigment-related and S-100β transcripts were quantified in 12 different melanoma cell lines and related to the amounts of 5-S-cysteinyldopa, pigment and S-100B protein. A real-time PCR method was used and the results were expressed as absolute number of transcripts per cell. Tyrosinase, tyrosinase-related protein (TRP)-1, TRP-2 and MART-1/Melan-A mRNA varied from undetectable (< 10−4 transcripts/cell) to 103 transcripts/cell, i.e. by a factor > 107 in the different cell lines. S-100β mRNA varied from 2.8 to 165 transcripts/cell, i.e. by a factor of 60. Tyrosinase, TRP-1 and TRP-2 mRNA correlated significantly with the amount of 5-S-cysteinyldopa, an intermediate pigment metabolite (P < 0.001, P < 0.001 and P < 0.01, respectively). The amount of S-100β mRNA correlated significantly with the amount of S-100B protein (P < 0.001). No cross-correlations were seen between the pigment-related and S-100-related analytes. We conclude that one reason behind the negative results of RT-PCR measurement of pigment-related mRNA may be that these transcripts are not always expressed in the particular cells present in the patient's blood. Furthermore, variation in the expression of the order of 107 must have great impact on the diagnostic sensitivity. Measurement of S-100β mRNA would be more sensitive, but the use of this transcript is hampered by its presence in the blood cells.
- 1 June 2002
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 12 (3) , 193-200
Quantitative relationships between pigment-related mRNA and biochemical melanoma markers in melanoma cell lines
The use of reverse transcription polymerase chain reaction (RT-PCR) analysis of melanoma-specific transcripts for the identification of circulating melanoma cells has shown very variable results in different studies on melanoma patients. We have therefore developed quantitative methods to study both analytical and biological variations as possible causes of this phenomenon. Pigment-related and S-100β transcripts were quantified in 12 different melanoma cell lines and related to the amounts of 5-S-cysteinyldopa, pigment and S-100B protein. A real-time PCR method was used and the results were expressed as absolute number of transcripts per cell. Tyrosinase, tyrosinase-related protein (TRP)-1, TRP-2 and MART-1/Melan-A mRNA varied from undetectable (< 10−4 transcripts/cell) to 103 transcripts/cell, i.e. by a factor > 107 in the different cell lines. S-100β mRNA varied from 2.8 to 165 transcripts/cell, i.e. by a factor of 60. Tyrosinase, TRP-1 and TRP-2 mRNA correlated significantly with the amount of 5-S-cysteinyldopa, an intermediate pigment metabolite (P < 0.001, P < 0.001 and P < 0.01, respectively). The amount of S-100β mRNA correlated significantly with the amount of S-100B protein (P < 0.001). No cross-correlations were seen between the pigment-related and S-100-related analytes. We conclude that one reason behind the negative results of RT-PCR measurement of pigment-related mRNA may be that these transcripts are not always expressed in the particular cells present in the patient's blood. Furthermore, variation in the expression of the order of 107 must have great impact on the diagnostic sensitivity. Measurement of S-100β mRNA would be more sensitive, but the use of this transcript is hampered by its presence in the blood cells.
- 1 August 2000
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 10 (4) , 363-369
The value of cysteinyldopa in the follow-up of disseminated malignant melanoma
In a series of 92 patients with malignant melanoma, clinical stage III or IV, both 5-S-cysteinyldopa (5SCD) and 6-hydroxy-5-methoxyindole-2-carboxylic acid (6H5MI2C) were measured in urine during chemotherapy. A total of 434 urine specimens were analysed. The sensitivity of 5SCD for the detection of stage III–IV melanoma was 83%, while the corresponding sensitivity of 6H5MI2C was 52%. Fifty per cent of patients with one metastatic site had increased 5SCD excretion, while all patients with four or more metastatic sites had increased excretion. A significant correlation was found between 5SCD decrease and clinical regression ( P < 0.001) and between 5SCD increase and clinical progression ( P < 0.001). Corresponding correlations were not found for 6H5MI2C. Increments in 5SCD excretion (median 269 μmol/mol creatinine) were seen for 83% of the occasions when clinical progression was recorded, and decrements in 5SCD excretion (median 145 μmol/mol creatinine) were seen for 85% of the occasions when clinical regression was seen. During clinical ‘stable disease’ increases in 5SCD excretion were seen in 59% and decreases in 41%. The median value of 5SCD changes for stable disease was 7.0 μmol/mol creatinine, indicating a chemical marker stability in many cases. We recommend the use of 5SCD in urine as a valuable, reliable and simple biochemical marker to use in the clinical follow-up of melanoma patients with advanced disease.
- 1 August 2000
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 10 (4) , 363-369
The value of cysteinyldopa in the follow-up of disseminated malignant melanoma
In a series of 92 patients with malignant melanoma, clinical stage III or IV, both 5-S-cysteinyldopa (5SCD) and 6-hydroxy-5-methoxyindole-2-carboxylic acid (6H5MI2C) were measured in urine during chemotherapy. A total of 434 urine specimens were analysed. The sensitivity of 5SCD for the detection of stage III–IV melanoma was 83%, while the corresponding sensitivity of 6H5MI2C was 52%. Fifty per cent of patients with one metastatic site had increased 5SCD excretion, while all patients with four or more metastatic sites had increased excretion. A significant correlation was found between 5SCD decrease and clinical regression ( P < 0.001) and between 5SCD increase and clinical progression ( P < 0.001). Corresponding correlations were not found for 6H5MI2C. Increments in 5SCD excretion (median 269 μmol/mol creatinine) were seen for 83% of the occasions when clinical progression was recorded, and decrements in 5SCD excretion (median 145 μmol/mol creatinine) were seen for 85% of the occasions when clinical regression was seen. During clinical ‘stable disease’ increases in 5SCD excretion were seen in 59% and decreases in 41%. The median value of 5SCD changes for stable disease was 7.0 μmol/mol creatinine, indicating a chemical marker stability in many cases. We recommend the use of 5SCD in urine as a valuable, reliable and simple biochemical marker to use in the clinical follow-up of melanoma patients with advanced disease.
- Open Access
- 1 July 2000
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 46 (7) , 921-927
Quantitative Analysis of Tyrosinase Transcripts in Blood
Background: Tyrosinase is an enzyme unique to pigment-forming cells. Methods using this transcript for detection of melanoma cells in blood have given divergent results. Quantitative analytical procedures are therefore needed to study the analytical performance of the methods. Methods: Mononucleated cells were isolated by Percoll centrifugation. RNA was isolated by each of three methods: UltraspecTM-II RNA isolation system, FastRNATM GREEN Kit, and QIAamp RNA Blood Mini Kit. cDNA was synthesized using random hexamer primers. A tyrosinase-specific product of 207 bp was amplified by PCR. As an internal standard (and competitor) we used a 207-bp cDNA with a base sequence identical to the tyrosinase target except for a 20-bp probe-binding region. The PCR products were identified by 2,4-dinitrophenol (DNP)-labeled probes specific for tyrosinase (5′DNP-GGGGAGCCTTGGGGTTCTGG-3′) and internal standard (5′DNP-CGGAGCCCCGAAACCACATC-3′) and quantified by ELISA. Results: The calibration curves were linear and had a broad dynamic measuring range. A detection limit (2 SD above zero) of 48 transcripts/mL of blood was obtained from a low control. The analytical imprecision was 50% and 48% at concentrations of 1775 and 17 929 transcripts/mL (n = 12 and 14, respectively). With the cell line SK-Mel 28 added to blood and RNA extracted with the Ultraspec, Fast RNA, and QIAamp RNA methods, we found (mean ± SD) 1716 ± 1341, 2670 ± 3174, and 24 320 ± 5332 transcripts/mL of blood. Corresponding values were 527 ± 497, 2497 ± 1033, 14 930 ± 1927 transcripts/mL of blood when the cell line JKM86-4 was added. One high-risk patient was followed by repeated analysis of tyrosinase transcripts in blood. The melanoma marker 5-S-cysteinyldopa in serum and urine was within reference values, but tyrosinase mRNA was slightly increased (120–168 transcripts/mL of blood). The tyrosinase mRNA increased to 1860 transcripts/mL concomitant with the increase in 5-S-cysteinyldopa; later a spleen metastasis was found. Conclusions: The results obtained with different RNA extraction methods illustrate the importance of quantitative methods for validation of methods. The use of QIAamp RNA improved the extraction efficiency considerably. Data from a case study suggest the assay is suitable in the follow-up of patients with high risk of developing metastases.
- 1 July 2000
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 46 (7) , 921-927
Open AccessQuantitative Analysis of Tyrosinase Transcripts in Blood
Background: Tyrosinase is an enzyme unique to pigment-forming cells. Methods using this transcript for detection of melanoma cells in blood have given divergent results. Quantitative analytical procedures are therefore needed to study the analytical performance of the methods. Methods: Mononucleated cells were isolated by Percoll centrifugation. RNA was isolated by each of three methods: UltraspecTM-II RNA isolation system, FastRNATM GREEN Kit, and QIAamp RNA Blood Mini Kit. cDNA was synthesized using random hexamer primers. A tyrosinase-specific product of 207 bp was amplified by PCR. As an internal standard (and competitor) we used a 207-bp cDNA with a base sequence identical to the tyrosinase target except for a 20-bp probe-binding region. The PCR products were identified by 2,4-dinitrophenol (DNP)-labeled probes specific for tyrosinase (5′DNP-GGGGAGCCTTGGGGTTCTGG-3′) and internal standard (5′DNP-CGGAGCCCCGAAACCACATC-3′) and quantified by ELISA. Results: The calibration curves were linear and had a broad dynamic measuring range. A detection limit (2 SD above zero) of 48 transcripts/mL of blood was obtained from a low control. The analytical imprecision was 50% and 48% at concentrations of 1775 and 17 929 transcripts/mL (n = 12 and 14, respectively). With the cell line SK-Mel 28 added to blood and RNA extracted with the Ultraspec, Fast RNA, and QIAamp RNA methods, we found (mean ± SD) 1716 ± 1341, 2670 ± 3174, and 24 320 ± 5332 transcripts/mL of blood. Corresponding values were 527 ± 497, 2497 ± 1033, 14 930 ± 1927 transcripts/mL of blood when the cell line JKM86-4 was added. One high-risk patient was followed by repeated analysis of tyrosinase transcripts in blood. The melanoma marker 5-S-cysteinyldopa in serum and urine was within reference values, but tyrosinase mRNA was slightly increased (120–168 transcripts/mL of blood). The tyrosinase mRNA increased to 1860 transcripts/mL concomitant with the increase in 5-S-cysteinyldopa; later a spleen metastasis was found. Conclusions: The results obtained with different RNA extraction methods illustrate the importance of quantitative methods for validation of methods. The use of QIAamp RNA improved the extraction efficiency considerably. Data from a case study suggest the assay is suitable in the follow-up of patients with high risk of developing metastases.
- 1 June 2000
- Vol. 10 (3) , 213-22
Quantitative analysis of tyrosinase and tyrosinase-related protein-2 mRNA from melanoma cells in blood by real-time polymerase chain reaction.
Several studies have evaluated the use of polymerase chain reaction (PCR) amplification of tyrosinase mRNA to detect melanoma cells in blood. However, contradictory results have been obtained from different groups. We therefore have developed and validated a quantitative PCR method for tyrosinase and tyrosinase-related protein-2 (TRP-2) mRNA. An important methodological finding was that high concentrations of reverse transcriptase or RNA sample inhibited the following PCR. This could be abolished by dilution of the cDNA sample before the PCR. Standard curves with a linear range over at least five logs were obtained with dilutions of melanoma cell cDNA. Controls (RNA and cDNA) consisting of melanoma cells (1000/ml) added to blood were analysed repeatedly over 3 months, resulting in means between 880 and 1074 AU/ml. The RNA controls were stable, whereas the cDNA controls, as well as the calibrators, showed a tendency to change over time. The variation in the RNA controls was 25% for tyrosinase and 22% for TRP-2. Seven stage III-IV melanoma patients were tested for tyrosinase and TRP-2 transcripts in blood drawn from a peripheral vein and from a Port-a-cath. Tyrosinase mRNA was found in three patients (0.8-12.4 AU/ml). For TRP-2, the same amount was found in the patients as in healthy donors. No differences were seen between blood from a peripheral vein and from the Port-a-cath. We here present fast and sensitive methods for the quantification of tyrosinase and TRP-2 mRNA in blood.
- 1 June 2000
- Vol. 10 (3) , 213-22
Quantitative analysis of tyrosinase and tyrosinase-related protein-2 mRNA from melanoma cells in blood by real-time polymerase chain reaction.
Several studies have evaluated the use of polymerase chain reaction (PCR) amplification of tyrosinase mRNA to detect melanoma cells in blood. However, contradictory results have been obtained from different groups. We therefore have developed and validated a quantitative PCR method for tyrosinase and tyrosinase-related protein-2 (TRP-2) mRNA. An important methodological finding was that high concentrations of reverse transcriptase or RNA sample inhibited the following PCR. This could be abolished by dilution of the cDNA sample before the PCR. Standard curves with a linear range over at least five logs were obtained with dilutions of melanoma cell cDNA. Controls (RNA and cDNA) consisting of melanoma cells (1000/ml) added to blood were analysed repeatedly over 3 months, resulting in means between 880 and 1074 AU/ml. The RNA controls were stable, whereas the cDNA controls, as well as the calibrators, showed a tendency to change over time. The variation in the RNA controls was 25% for tyrosinase and 22% for TRP-2. Seven stage III-IV melanoma patients were tested for tyrosinase and TRP-2 transcripts in blood drawn from a peripheral vein and from a Port-a-cath. Tyrosinase mRNA was found in three patients (0.8-12.4 AU/ml). For TRP-2, the same amount was found in the patients as in healthy donors. No differences were seen between blood from a peripheral vein and from the Port-a-cath. We here present fast and sensitive methods for the quantification of tyrosinase and TRP-2 mRNA in blood.